Comparison of benzimidazole nucleosides and ganciclovir on the in vitro proliferation and colony formation of human bone marrow progenitor cells

British Journal of Haematology

Volumn 93, Issue 2, 1996, Pages 273-279

  Nassiri, M Reza ^a,c   Emerson, Stephen G ^a   Devivar, Rodrigo V ^a   Townsend, Leroy B ^a   Drach, John C ^a   Taichman, Russell S ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

antivirals; bone marrow toxicity; colony formation; erythroid; granulocyte macrophage

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; GANCICLOVIR;

ARTICLE; BONE MARROW CELL; BONE MARROW TOXICITY; CLONOGENIC ASSAY; CONTROLLED STUDY; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0344400941     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.5231066.x     Document Type: Article

References (30)

1. Alford, C.A. & Britt, W.J. (1993) Cytomegalovirus. The Human Herpesviruses (ed. by B. Roizman, R. J. Whitley and C. Lopez), pp. 227-255. Raven Press, New York.
2. Appelbaum, F.R., Meyers, J.D., Deeg, J., Schuening, T.G.F. & Storb, R. (1988) Toxicity trial of prophylactic 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (ganciclovir) after marrow transplantation in dogs. Antimicrobial Agents and Chemotherapy, 32, 271-273.
3. Buhles, W.C., Mastre, B.J., Tinker, A.J., Strand, V. & Kortez, S.H., Syntex Collaborative Ganciclovir Treatment Group (1988) Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Review of Infectious Diseases, 3, S495-S506.
4. Castella, A., Croxson, T.S., Mildvan, D., Witt, D.H. & Zalusky, R. (1985) The bone marrow in AIDS: a histologic, hematologic, and microbiologic study. American Journal of Clinical Pathology, 84, 424-432.
5. Chrisp, P. & Clissold, S.P. (1991) Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis, Drugs, 41, 104-129.
6. Drach, J.C., Bush, P.M., Ptak, R.G., Devivar, R.V., Townsend, L.B., Davis, M.G., Underwood, M.R. & Biron, K.K. (1995) Halogenated benzimidazole 5′-deoxyribonucleosides are potent and selective inhibitors of human cytomegalovirus replication. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract H112.
7. Drach, J.C., Townsend, L.B., Nassiri, M.R., Turk, S.R., Coleman, L.A., Devivar, R.V., Genzlinger, G., Kreske, E.D., Renau, T.R., Westerman, A.C. & Shipman, C., Jr. Biron, K.K., Dornsife, R. & Kern, E.R. (1992) Benzimidazole ribonucleosides: a new class of antivirals with potent and selective activity against human cytomegalovirus. Antiviral Research, 21. (Suppl. 1), 49.
8. Drew, W.L. (1991) Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance. Journal of Acquired Immunodeficiency Syndrome, 1, S42-S46.
9. Faulds, D. & Heel, R.C. (1990) Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs, 39, 597-638.
10. Field, A.K. & Biron, K.K. (1994) The end of innocence' revisited: resistance of herpesviruses to antiviral drugs. Clinical Microbiology Review. 7, 1-13.
11. Fletcher, C., Sawchuk, R., Chinnock, M.T., de Miranda, P. & Balfour, H.H., Jr (1986) Human pharmacokinetics of the antiviral drug DHPG. Clinical Pharmacology and Therapeutics, 40, 281-286.
12. Goldstein, A. (1964) Analysis of a single curve with graded responses. Biostatistics: an Introductory Text, pp. 156-161. MacMillan, New York.
13. Good, S.S., Owens, B.S., Townsend, L.B. & Drach, J.C. (1994) The disposition in rats and monkeys of 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl)-benzimidazole (BDCRB) and its 2,5,6-trichloro congener (TCRB). Antiviral Research, 23, (Suppl. 1). 103.
14. Knox, K.K., Drobyski, W.R. & Carrigan, D.R. (1991) Cytomegalovirus isolate resistant to ganciclovir and foscarnet from marrow transplant patient. Lancet, 337, 1292-1293.
15. Lagneaux, L., Delforge, A., Snoek, R., Stryckmans, P. & Bron, D. (1994) Decreased production of cytokines after cytomegalovirus infection of marrow-derived stromal cells. Experimental Hematology, 22, 26-30.
16. Lewis, A.F., Drach, J.C., Fennewald, S.M., Huffman, J.H., Ptak, R.G., Sommadossi, J-P., Revankar, G.R. & Rando, R.F. (1994) Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring system. Antimicrobial Agents and Chemotherapy, 38, 2889-2895.
17. McKenzie, R., Travis, W.D. & Masur, H. (1991) The causes of death in patients with human immunodeficiency virus infection: a clinical and pathological study with emphasis on the role of pulmonary diseases. Medicine, 70, 326-343.
18. Palestine, A.G., Polis, M.A., Smet, M.D., Baird, B.F., Falloon, J. Kovacs, J.A., Davey, R.T., Zurlo, J.J., Zunich, K.M., Davis, M., Hubbard, L., Brothers, R., Ferris, F.L., Chew, E., Davis, J.L., Rubin, B.I., Mellow, S.D., Metcalf, J.A., Mansichewitz, J., Minor, J.R., Nussenblatt, R.B., Masur, H. & Lane, C. (1991) A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Annals of Internal Medicine, 11, 665-673.
19. Perkocha, L.A. & Rodgers, G.M. (1988) Hematologic aspects of human immunodeficiency virus infection: laboratory and clinical considerations American Journal of Hematology, 29, 94-105.
20. Roche Laboratories (1996) Cytovene® IV (ganciclovir for injection). Physicians' Desk Reference, 50th edn. pp. 2104-2110.
21. Rubin, R.H. (1990) Impact of cytomegalovirus infection on organ transplant recipients. Review of Infectious Diseases, 12, S754-766.
22. Scadden, D.T., Wang, A., Zsebo, K.M. & Groopman, J.E. (1994) In vitro effects of stem-cell factor or interleukin-3 on myelosuppression associated with AIDS. AIDS, 8, 193-196.
23. Snoek, R., Langneaux, L., Delforge, A., Bron, D., Van der Auwera, P., Stryckmans, P., Balzarini, J. & De Clercq, E. (1990) Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro. European Journal of Clinical Microbiology and Infectious Diseases, 9, 615-619.
24. Tamm, I., Folkers, K., Shunk, C.H. & Horsfall, F.L. (1954) Inhibition of influenza virus multiplication by N-glycosides of benzimidazoles. Journal of Experimental Medicine, 99, 227-250.
25. Townsend, L.B., Devivar, R.V., Turk, S.R., Nassiri, M.R. & Drach, J.C. (1995) Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(β-D-ribofuranosyl) benzimidazoles. Journal of Medicinal Chemistry, 38, 4098-4105.
26. Treacy, M., Lai, L., Costello, C. & Clark, A.L. (1987) Peripheral blood and bone marrow abnormalities in patients with HIV-related disease. British Journal of Haematology, 65, 289-294.
27. Underwood, M.R., Biron, K.K., Hemphill, M.L., Miller, T.J., Stanat, S.C., Dornsife, R.E., Drach, J.C., Townsend, L.B., Edwards, C.A. & Harvey, R.J. (1993) High molecular weight HCMV DNA does not properly mature in the presence of 2-bromo-5,6-dichloro-l-β-D-ribofuranosylbenzimidazole (BDCRB). Herpesvirus Workshop, Pittsburg, Pa., July 1993.
28. Underwood, M.R., Stanat, S.C., Drach, J.C., Harvey, R.J. & Biron, K.K. (1994) Inhibition of HCMV DNA processing by a new class of anti-HCMV compounds is mediated through the UL89 gene product. Herpesvirus Workshop, Vancouver, B.C., August 1994.
29. Von Bueltzingsloewen, A., Bordigoni, P., Witz, F., Bene, M.C., Schmitt, C., Lacour, B. & Sommelet, D. (1993) Prophylactic use of ganciclovir for allogenic bone marrow transplant recipients. Bone Marrow Transplantation, 12, 197-202.
30. Winston, D.J., Ho, W.G., Bartini, K., Holland, G.N., Mitsuya, R.T., Gale, R.P., Busuttil, R.W. & Champlin, R.E. (1988) Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunocompromised patients. Review of Infectious Diseases, 3, 547-553.